Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FIRST: Mylan, Micro...

    FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-12-24T09:45:05+05:30  |  Updated On 18 Aug 2021 3:47 PM IST

    Sales of Eliquis, which Bristol-Myers co-developed with Pfizer, rose 22% to $1.93 billion and made up about 30% of the Bristol-Myers' total revenues in the latest reported quarter.


    New Delhi: The U.S. Food and Drug Administration said on Monday it has approved the first generic version of Bristol-Myers Squibb Co and Pfizer Inc's blood thinner Eliquis.


    The approval was granted to Micro Labs Ltd and Mylan Pharmaceuticals Inc, the agency said.


    Sales of Eliquis, which Bristol-Myers co-developed with Pfizer, rose 22% to $1.93 billion and made up about 30% of the Bristol-Myers' total revenues in the latest reported quarter.


    Read Also: Patent Infringement: Bristol-Myers wins case against Gilead; awarded USD 752 million in damages


    Eliquis is an approved treatment to reduce the risk of stroke in patients with irregular heartbeat or atrial fibrillation.


    The drug is also used to prevent blood clots in veins located deep in the body and in lungs.


    Read Also: Bristol-Myers, bluebird cancer therapy meets goal in mid-stage trial

    blood clot preventionblood thinnerBMS​Bristol Myers SquibbBristol-MyersBristol-Myers Squibb CoEliquisMicro LabsMylanPfizerpharmapharma companypharma newsUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok